DTBN
Pulsar + sobre un periodo para mostrar cada año
Uncertainties about new oral anticoagulants in atrial fibrillation. Deficiencies and irregularities in the authorization process
Safety considerations for NSAIDs
The EMPA-REG OUTCOME trial (empagliflozin). A critical appraisal. The power of truth, the truth of power
New antidiabetic drugs: What place should they have in therapeutics?
Contribution of bronchodilator combination therapies to COPD